Brief: Xbrane, Intas To Develop Nivolumab Biosimilar

Xbrane Biopharma AB

19/11/2024 11:28

Nov 19 (Reuters) - Intas Pharmaceuticals Ltd  INTA.NS :
    * XBRANE AND INTAS ENTER INTO A GLOBAL LICENSING AGREEMENT
TO
JOINTLY DEVELOP NIVOLUMAB BIOSIMILAR REFERENCING OPDIVO®
    * TO GET UPFRONT PAYMENT OF EUR 10 MILLIONS FROM INTAS AND
DEVELOPMENT MILESTONE PAYMENTS OF EUR 3 MILLION

Source text:  ID:nMFN10tG7y 
Further company coverage:  INTA.NS 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))